We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Mobile DNA Test Developed for HIV

By LabMedica International staff writers
Posted on 19 Jun 2014
An efficient test to detect signs of human immunodeficiency virus (HIV) and its progress in patients in low-resource settings is being developed using recombinase polymerase amplification (RPA). More...


The current gold standard to diagnose HIV in infants and to monitor viral load depends on laboratory equipment and technical expertise generally available only in clinics, while the new assay features a nucleic acid-based test that can be performed at the site of care.

Bioengineers at Rice University (Houston, TX, USA) developed a new technique that would replace a complex procedure based on polymerase chain reaction (PCR) with one that relies on RPA, a method that quickly amplifies genetic markers found in blood to levels where they can be easily counted. In the test the team calls quantitative RPA (qRPA), a specific sequence in HIV DNA is targeted and tagged with fluorescent probes that can be seen and quantified by a portable machine. Software analysis of the fluorescing DNA allows clinicians to determine with great accuracy whether the virus is present in a patient's blood and/or how much is there.

Amplification and real-time data collection were performed in a CFX96 Real Time qPCR machine (Bio-Rad; Hercules, CA, USA). Preliminary RPA experiments detecting HIV-1 DNA and internal positive control sequence (IPC) DNA in separate reactions demonstrated that the time at which detectable amplification begins, increases with decreasing DNA concentration, suggesting that quantification of DNA with RPA is feasible. The assay could potentially be optimized for greater accuracy by collecting fluorescence data more frequently or decreasing the reaction rate by either decreasing the concentration of magnesium acetate in the reaction or amplifying at a lower temperature.

This assay was designed for use with an inexpensive, point-of-care fluorescence reader, such as the commercially available Twista portable real-time fluorometer (TwistDx, Ltd.; Cambridge, UK) or the ESEQuant Tube Scanner (Qiagen; Valencia, CA, USA). To be clinically viable, a DNA-based test for HIV has to be able to quantify virus loads over four orders of magnitude, from very low to very high; the scientists reported that the qRPA test easily meets that goal. The study was published on May 26, 2014, in the journal Analytical Chemistry.

Related Links:

Rice University
Bio-Rad
TwistDx Ltd.




New
Gold Member
Hematology Analyzer
Medonic M32B
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.